Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(1)
•••
Post by skyhigh123on May 06, 2018 10:25am
115 Views
Post# 27988555

A few articles new and older / it’s a sunny morning in BC

A few articles new and older / it’s a sunny morning in BC
1.

Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada.

Tarride JE, Hopkins RB, Burke N, Guertin JR, O'Reilly D, Fell CD, Dion G, Kolb M.

Clinicoecon Outcomes Res. 2018 Feb 22;10:127-137. doi: 10.2147/CEOR.S154323. eCollection 2018.

PMID:
 
29503576
 
Free PMC Article

Similar articles

2.

A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84.

Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, Gagnon W, Hince K, Tremblay M, Geerts L, Kennedy CRJ, Hbert RL, Gutsol A, Holterman CE, Kamto E, Gervais L, Ouboudinar J, Richard J, Felton A, Laverdure A, Simard JC, Ltourneau S, Cloutier MP, Leblond FA, Abbott SD, Penney C, Duceppe JS, Zacharie B, Dupuis J, Calderone A, Nguyen QT, Harris RC, Laurin P.

Am J Pathol. 2018 May;188(5):1132-1148. doi: 10.1016/j.ajpath.2018.01.009. Epub 2018 Feb 16.

PMID:
 
29454750
 
Free Article

Similar articles

3.

Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency.

Shapiro AD, Nakar C, Parker JM, Albert GR, Moran JE, Thibaudeau K, Thukral N, Hardesty BM, Laurin P, Sandset PM.

Blood. 2018 Mar 22;131(12):1301-1310. doi: 10.1182/blood-2017-09-806729. Epub 2018 Jan 10.

PMID:
 
29321155
 
Free PMC Article

Similar articles

4.

Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study.

Kempton CL, Wang M, Recht M, Neff A, Shapiro AD, Soni A, Kulkarni R, Buckner TW, Batt K, Iyer NN, Cooper DL.

Patient Prefer Adherence. 2017 Sep 19;11:1603-1612. doi: 10.2147/PPA.S141389. eCollection 2017.

PMID:
 
29033549
 
Free PMC Article

Similar articles

5.

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R.

BMJ Open Respir Res. 2017 Sep 17;4(1):e000212. doi: 10.1136/bmjresp-2017-000212. eCollection 2017.

PMID:
 
29018526
 
Free PMC Article

Similar articles

6.

Interleukin-36β provides protection against HSV-1 infection, but does not modulate initiation of adaptive immune responses.

Milora KA, Uppalapati SR, Sanmiguel JC, Zou W, Jensen LE.

Sci Rep. 2017 Jul 19;7(1):5799. doi: 10.1038/s41598-017-05363-4.

PMID:
 
28724920
 
Free PMC Article

Similar articles

7.

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.

Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M.

Thorax. 2017 Feb;72(2):148-153. doi: 10.1136/thoraxjnl-2016-208819. Epub 2016 Oct 5.

PMID:
 
27708114
 
Free PMC Article

Similar articles

8.

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.

Wuyts WA, Kolb M, Stowasser S, Stansen W, Huggins JT, Raghu G.

Lung. 2016 Oct;194(5):739-43. doi: 10.1007/s00408-016-9912-1. Epub 2016 Jul 4.

PMID:
 
27377558
 
Free PMC Article

Similar articles

9.

Assessment of Saliva as a Potential Biofluid for Biodosimetry: A Pilot Metabolomics Study in Mice.

Laiakis EC, Strawn SJ, Brenner DJ, Fornace AJ Jr.

Radiat Res. 2016 Jul;186(1):92-7. doi: 10.1667/RR14433.1. Epub 2016 Jun 22.

PMID:
 
27332953
 
Free PMC Article

Similar articles

10.

Affinity interactions of human immunoglobulin G with short peptides: role of ligand spacer on binding, kinetics, and mass transfer.

Shen F, Rojas OJ, Genzer J, Gurgel PV, Carbonell RG.

Anal Bioanal Chem. 2016 Mar;408(7):1829-41. doi: 10.1007/s00216-015-9135-y. Epub 2015 Nov 9.

PMID:
 
26549116

Similar articles

11.
 
 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities